IN2014MN01944A - - Google Patents

Info

Publication number
IN2014MN01944A
IN2014MN01944A IN1944MUN2014A IN2014MN01944A IN 2014MN01944 A IN2014MN01944 A IN 2014MN01944A IN 1944MUN2014 A IN1944MUN2014 A IN 1944MUN2014A IN 2014MN01944 A IN2014MN01944 A IN 2014MN01944A
Authority
IN
India
Prior art keywords
compounds
combinations
cell death
induction
methods
Prior art date
Application number
Inventor
Paul J Hergenrother
Rachel C Botham
Timothy M Fan
Mark J Gilbert
Michael K Handley
Gregory J Riggins
Theodore M Tarasow
Avadhut Joshi
Original Assignee
Univ Illinois
Vanquish Oncology Inc
Univ Johns Hopkins
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Illinois, Vanquish Oncology Inc, Univ Johns Hopkins filed Critical Univ Illinois
Publication of IN2014MN01944A publication Critical patent/IN2014MN01944A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4188—1,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/008—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Abstract

The invention provides compositions and methods for the induction of cell death for example cancer cell death. Combinations of compounds and related methods of use are disclosed including the use of compounds in therapy for the treatment of cancer and selective induction of apoptosis in cells. The disclosed drug combinations can have lower neurotoxicity effects than other compounds and combinations of compounds.
IN1944MUN2014 2012-03-06 2013-03-06 IN2014MN01944A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261607103P 2012-03-06 2012-03-06
PCT/US2013/029391 WO2013134398A1 (en) 2012-03-06 2013-03-06 Procaspase combination therapy for glioblastoma

Publications (1)

Publication Number Publication Date
IN2014MN01944A true IN2014MN01944A (en) 2015-07-10

Family

ID=49117298

Family Applications (1)

Application Number Title Priority Date Filing Date
IN1944MUN2014 IN2014MN01944A (en) 2012-03-06 2013-03-06

Country Status (15)

Country Link
US (5) US9421202B2 (en)
EP (2) EP2822546B1 (en)
JP (2) JP6222608B2 (en)
KR (1) KR102075811B1 (en)
CN (1) CN104540501B (en)
AU (1) AU2013230985B2 (en)
BR (1) BR112014022123B1 (en)
CA (1) CA2866020C (en)
DK (2) DK3290035T3 (en)
ES (2) ES2646008T3 (en)
HK (1) HK1204985A1 (en)
IN (1) IN2014MN01944A (en)
MX (1) MX359209B (en)
RU (1) RU2636234C2 (en)
WO (1) WO2013134398A1 (en)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008134474A2 (en) 2007-04-27 2008-11-06 The Board Of Trustees Of The University Of Illinois Compositions and methods including cell death inducers and procaspase activation
WO2016197129A1 (en) * 2015-06-05 2016-12-08 The Board Of Trustees Of The University Of Illinois Pac-1 combination therapy
KR101712638B1 (en) 2015-08-19 2017-03-07 한국과학기술연구원 System and method of controlling protein expression by using PAC-1 and doxycycline antagonist containing PCA-1 as an effective ingredient
MX2020004991A (en) 2017-11-17 2022-02-10 Univ Illinois Cancer therapy by degrading dual mek signaling.
US20220175822A1 (en) * 2019-03-05 2022-06-09 Dow Global Technologies Llc Inducing caspase activity
MX2021014758A (en) * 2019-05-30 2022-03-11 Univ Illinois Procaspase-3 activation and immunotherapy for treatment of cancer.

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5260291A (en) 1981-08-24 1993-11-09 Cancer Research Campaign Technology Limited Tetrazine derivatives
US4938949A (en) 1988-09-12 1990-07-03 University Of New York Treatment of damaged bone marrow and dosage units therefor
US6403765B1 (en) 1998-06-16 2002-06-11 Thomas Jefferson University Truncated Apaf-1 and methods of use thereof
AU5205499A (en) 1998-07-27 2000-02-21 Pharmacia & Upjohn Company Method for autoactivation of procaspase 8
US6110691A (en) 2000-01-06 2000-08-29 Board Of Regents, The University Of Texas System Activators of caspases
US6608026B1 (en) 2000-08-23 2003-08-19 Board Of Regents, The University Of Texas System Apoptotic compounds
AU2002241508A1 (en) 2000-11-20 2002-06-24 Lawrence C. Fritz Membrane derived caspase-3, compositions comprising the same and methods of use therefor
US6878743B2 (en) 2001-09-18 2005-04-12 Sunesis Pharmaceuticals, Inc. Small molecule inhibitors of caspases
WO2004066958A2 (en) 2003-01-30 2004-08-12 The Trustees Of Princeton University Caspase-9:bir3 domain of xiap complexes and methods of use
US7632972B2 (en) 2003-10-30 2009-12-15 The Board Of Trustees Of The University Of Illionis Compounds and methods for treatment of cancer and modulation of programmed cell death for melanoma and other cancer cells
US8440610B2 (en) * 2004-11-12 2013-05-14 Massachusetts Institute Of Technology Mapkap kinase-2 as a specific target for blocking proliferation of P53-defective cells
WO2008134474A2 (en) 2007-04-27 2008-11-06 The Board Of Trustees Of The University Of Illinois Compositions and methods including cell death inducers and procaspase activation
CN101184491A (en) * 2005-05-26 2008-05-21 伊利诺伊大学评议会 Selective apoptotic induction in cancer cells including activation of procaspase-3
US20070049602A1 (en) 2005-05-26 2007-03-01 The Board Of Trustees Of The University Of Illinois Selective Apoptotic Induction in Cancer Cells Including Activation of Procaspase-3
EP1896421B1 (en) 2005-06-23 2011-09-14 Merck Sharp & Dohme Corp. Benzocycloheptapyridines as inhibitors of the receptor tyrosine kinase met
TWI373473B (en) 2005-09-02 2012-10-01 Otsuka Pharma Co Ltd Anticancer agent
EP1940395A2 (en) * 2005-09-16 2008-07-09 Schering Corporation Pharmaceutical compositions and methods using temozolomide and a protein kinase inhibitor
US20070111936A1 (en) * 2005-11-15 2007-05-17 Vladimir Pak Complex of alpha-fetoprotein and inducers of apoptosis for the treatment of cancer
US7886969B2 (en) 2005-12-06 2011-02-15 Visa U.S.A. Inc. Method and system for loading and reloading portable consumer devices
CA2651395A1 (en) 2006-05-19 2007-11-29 Board Of Trustees Of The University Of Illinois Phosphorous containing compounds including triphenylmethylphosphonate esters for the treatment of melanoma and other cancers
RU2360692C1 (en) 2007-12-21 2009-07-10 Тихоокеанский Институт Биоорганической Химии Дальневосточного Отделения Российской Академии Наук (Тибох Дво Ран) Agent stimulating apoptosis of human leukaemia cells
BRPI0907162A2 (en) 2008-01-11 2015-07-07 Univ California Compound, pharmaceutical composition and methods for activating procaspase performer 3, 6 and / or 7 and for treating a disease state in a mammal
US20100291214A1 (en) * 2008-12-23 2010-11-18 Armark Authentication Technologies, Llc Three-dimensional microfiber extrudate structure and process for forming three-dimensional microfiber extrudate structure
AU2010210403B2 (en) 2009-02-09 2016-07-28 The Board Of Trustees Of The University Of Illinois Design, synthesis and evaluation of procaspase activating compounds as personalized anti-cancer drugs
TWI386203B (en) * 2011-01-07 2013-02-21 Univ China Medical Pharmaceutical composition for treating brain cancer or reducing temozolomide-resistance of brain cancer cells and uses of the same
WO2012118978A1 (en) * 2011-03-03 2012-09-07 The Regents Of The University Of Colorado, A Body Corporate Methods for treating oncovirus positive cancers

Also Published As

Publication number Publication date
MX2014010714A (en) 2015-03-10
ES2738448T3 (en) 2020-01-22
AU2013230985A1 (en) 2014-10-16
US20190099419A1 (en) 2019-04-04
CN104540501A (en) 2015-04-22
CA2866020A1 (en) 2013-09-12
RU2636234C2 (en) 2017-11-21
US20240082241A1 (en) 2024-03-14
KR102075811B1 (en) 2020-02-10
EP3290035A1 (en) 2018-03-07
ES2646008T3 (en) 2017-12-11
JP6222608B2 (en) 2017-11-01
WO2013134398A1 (en) 2013-09-12
EP2822546A4 (en) 2015-10-28
US20170042886A1 (en) 2017-02-16
JP2018052932A (en) 2018-04-05
US10874666B2 (en) 2020-12-29
DK2822546T3 (en) 2017-10-30
AU2013230985B2 (en) 2016-05-12
US9421202B2 (en) 2016-08-23
DK3290035T3 (en) 2019-08-05
CA2866020C (en) 2020-09-22
RU2014139955A (en) 2016-04-27
BR112014022123A2 (en) 2017-06-20
CN104540501B (en) 2016-11-23
EP3290035B1 (en) 2019-05-15
US10085978B2 (en) 2018-10-02
US20150025083A1 (en) 2015-01-22
EP2822546B1 (en) 2017-07-12
HK1204985A1 (en) 2015-12-11
JP2015509964A (en) 2015-04-02
BR112014022123B1 (en) 2022-09-20
EP2822546A1 (en) 2015-01-14
KR20140143771A (en) 2014-12-17
US20210290616A1 (en) 2021-09-23
US11844798B2 (en) 2023-12-19
MX359209B (en) 2018-09-19

Similar Documents

Publication Publication Date Title
IN2014MN01945A (en)
PH12016501139B1 (en) Bicyclic heterocycle compounds and their uses in therapy
MX366804B (en) R-spondin translocations and methods using the same.
MX2021001878A (en) Methods and compositions for enhancing cd4+ regulatory t cells.
EP2904106A4 (en) Compositions and methods for targeting stromal cells for the treatment of cancer
MX371108B (en) Pyrimidopyrimidinones useful as wee-1 kinase inhibitors.
MX2015006478A (en) Glutamase inhibitors and method of use.
MX360404B (en) Compounds for inhibiting cell proliferation in egfr-driven cancers.
GB201106750D0 (en) Novel compounds
NZ630805A (en) Pharmaceutical combinations comprising a thionucleotide analog
MX2015004771A (en) Methods of treating cancer.
MX356525B (en) Aav -vectors for use in gene therapy of choroideremia.
EP2844736A4 (en) Modified bacteria and uses thereof for treatment of cancer or tumor
PH12018502569A1 (en) Anti-androgens for the treatment of non-metastatic castrate-resistant prostate cancer
IL238177A0 (en) Methods and compositions for the treatment of cancer
MX2014012477A (en) Pyrrolopyrazone inhibitors of tankyrase.
IL239007B (en) Eribulin for use in the treatment of breast cancer
MX356755B (en) Fumigillol type compounds and methods of making and using same.
MX2015001551A (en) Enzyme-activating compounds and compositions.
IN2014MN01944A (en)
MX2017015532A (en) Pac-1 combination therapy.
WO2013131089A3 (en) Potent anticancer activity via dual compound activation
MX2014012535A (en) Combination therapy of anti-mif antibodies and chemotherapeutics.
GB2528604A (en) Modulation of asymmetric proliferation
MX350868B (en) MEDICAMENTS and METHODS FOR TREATING CANCER.